Therapeutic angiogenesis and vasculogenesis for tissue regeneration

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Therapeutic angiogenesis/vasculogenesis holds promise for the cure of ischaemic disease. The approach postulates the manipulation of spontaneous healing response by supplementation of growth factors or transplantation of vascular progenitor cells. These supplements are intended to foster the formation of arterial collaterals and promote the regeneration of damaged tissues. Angiogenic factors are generally delivered in the form of recombinant proteins or by gene transfer using viral vectors. In addition, new non-viral methods are gaining importance for their safer profile. The association of growth factors with different biological activity might offer distinct advantages in terms of efficacy, yet combined approaches require further optimization. Alternatively, substances with pleiotropic activity might be considered, by virtue of their ability to target multiple mechanisms. For instance, some angiogenic factors not only stimulate the growth of arterioles and capillaries, but also inhibit vascular destabilization triggered by metabolic and oxidative stress. Transplantation of endothelial progenitor cells was recently proposed for the treatment of peripheral and myocardial ischaemia. Progenitor cells can be transplanted either without any preliminary conditioning or after ex vivo genetic manipulation. Delivery of genetically modified progenitor cells eliminates the drawback of immune response against viral vectors and makes feasible repeating the therapeutic procedure in case of injury recurrence. It is envisioned that these new approaches of regenerative medicine will open unprecedented opportunities for the care of life-threatening diseases.

Original languageEnglish
Pages (from-to)315-326
Number of pages12
JournalExperimental Physiology
Volume90
Issue number3
DOIs
Publication statusPublished - May 2005

Fingerprint

Regeneration
Stem Cells
Angiogenesis Inducing Agents
Blood Vessels
Intercellular Signaling Peptides and Proteins
Transplantation
Physiological Stress
Regenerative Medicine
Arterioles
Recombinant Proteins
Myocardial Ischemia
Oxidative Stress
Therapeutics
Recurrence
Wounds and Injuries
Growth
Genes
Endothelial Progenitor Cells

ASJC Scopus subject areas

  • Physiology

Cite this

Therapeutic angiogenesis and vasculogenesis for tissue regeneration. / Madeddu, Paolo.

In: Experimental Physiology, Vol. 90, No. 3, 05.2005, p. 315-326.

Research output: Contribution to journalArticle

@article{759928243a0e48469ffaec4fe804b5e1,
title = "Therapeutic angiogenesis and vasculogenesis for tissue regeneration",
abstract = "Therapeutic angiogenesis/vasculogenesis holds promise for the cure of ischaemic disease. The approach postulates the manipulation of spontaneous healing response by supplementation of growth factors or transplantation of vascular progenitor cells. These supplements are intended to foster the formation of arterial collaterals and promote the regeneration of damaged tissues. Angiogenic factors are generally delivered in the form of recombinant proteins or by gene transfer using viral vectors. In addition, new non-viral methods are gaining importance for their safer profile. The association of growth factors with different biological activity might offer distinct advantages in terms of efficacy, yet combined approaches require further optimization. Alternatively, substances with pleiotropic activity might be considered, by virtue of their ability to target multiple mechanisms. For instance, some angiogenic factors not only stimulate the growth of arterioles and capillaries, but also inhibit vascular destabilization triggered by metabolic and oxidative stress. Transplantation of endothelial progenitor cells was recently proposed for the treatment of peripheral and myocardial ischaemia. Progenitor cells can be transplanted either without any preliminary conditioning or after ex vivo genetic manipulation. Delivery of genetically modified progenitor cells eliminates the drawback of immune response against viral vectors and makes feasible repeating the therapeutic procedure in case of injury recurrence. It is envisioned that these new approaches of regenerative medicine will open unprecedented opportunities for the care of life-threatening diseases.",
author = "Paolo Madeddu",
year = "2005",
month = "5",
doi = "10.1113/expphysiol.2004.028571",
language = "English",
volume = "90",
pages = "315--326",
journal = "Experimental Physiology",
issn = "0958-0670",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Therapeutic angiogenesis and vasculogenesis for tissue regeneration

AU - Madeddu, Paolo

PY - 2005/5

Y1 - 2005/5

N2 - Therapeutic angiogenesis/vasculogenesis holds promise for the cure of ischaemic disease. The approach postulates the manipulation of spontaneous healing response by supplementation of growth factors or transplantation of vascular progenitor cells. These supplements are intended to foster the formation of arterial collaterals and promote the regeneration of damaged tissues. Angiogenic factors are generally delivered in the form of recombinant proteins or by gene transfer using viral vectors. In addition, new non-viral methods are gaining importance for their safer profile. The association of growth factors with different biological activity might offer distinct advantages in terms of efficacy, yet combined approaches require further optimization. Alternatively, substances with pleiotropic activity might be considered, by virtue of their ability to target multiple mechanisms. For instance, some angiogenic factors not only stimulate the growth of arterioles and capillaries, but also inhibit vascular destabilization triggered by metabolic and oxidative stress. Transplantation of endothelial progenitor cells was recently proposed for the treatment of peripheral and myocardial ischaemia. Progenitor cells can be transplanted either without any preliminary conditioning or after ex vivo genetic manipulation. Delivery of genetically modified progenitor cells eliminates the drawback of immune response against viral vectors and makes feasible repeating the therapeutic procedure in case of injury recurrence. It is envisioned that these new approaches of regenerative medicine will open unprecedented opportunities for the care of life-threatening diseases.

AB - Therapeutic angiogenesis/vasculogenesis holds promise for the cure of ischaemic disease. The approach postulates the manipulation of spontaneous healing response by supplementation of growth factors or transplantation of vascular progenitor cells. These supplements are intended to foster the formation of arterial collaterals and promote the regeneration of damaged tissues. Angiogenic factors are generally delivered in the form of recombinant proteins or by gene transfer using viral vectors. In addition, new non-viral methods are gaining importance for their safer profile. The association of growth factors with different biological activity might offer distinct advantages in terms of efficacy, yet combined approaches require further optimization. Alternatively, substances with pleiotropic activity might be considered, by virtue of their ability to target multiple mechanisms. For instance, some angiogenic factors not only stimulate the growth of arterioles and capillaries, but also inhibit vascular destabilization triggered by metabolic and oxidative stress. Transplantation of endothelial progenitor cells was recently proposed for the treatment of peripheral and myocardial ischaemia. Progenitor cells can be transplanted either without any preliminary conditioning or after ex vivo genetic manipulation. Delivery of genetically modified progenitor cells eliminates the drawback of immune response against viral vectors and makes feasible repeating the therapeutic procedure in case of injury recurrence. It is envisioned that these new approaches of regenerative medicine will open unprecedented opportunities for the care of life-threatening diseases.

UR - http://www.scopus.com/inward/record.url?scp=18844401151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844401151&partnerID=8YFLogxK

U2 - 10.1113/expphysiol.2004.028571

DO - 10.1113/expphysiol.2004.028571

M3 - Article

C2 - 15778410

AN - SCOPUS:18844401151

VL - 90

SP - 315

EP - 326

JO - Experimental Physiology

JF - Experimental Physiology

SN - 0958-0670

IS - 3

ER -